Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.
about
Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.The regulatory role of DPP4 in atherosclerotic disease.Cardiac Computed Tomography Angiographic Findings as Predictors of Late Heart Failure in an Asymptomatic Diabetic Cohort: An 8-Year Prospective Follow-Up Study.The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use.Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy.Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real WThe year in cardiology 2017: heart failure.Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle
P2860
Q33660548-8D7C5A09-260B-4305-99B1-BB9C9F969448Q33805518-B9AA5A2C-19A8-4922-90C6-D833EB761057Q38619761-59E12709-4C62-4ECC-B5DD-FC87DA2EB121Q38927264-565EE114-0F8C-4E49-A41C-A790EC772F84Q39164190-3F6983B5-15AC-4FCC-B211-C0366541373EQ47614541-465D33B5-BB3C-4336-81E5-8230C2F3E8BAQ47687852-0E3659E2-49E4-4152-BEB9-F8CAEE48639FQ49587923-B532C8FF-0048-45FA-B7D5-ECDA94A80CE5Q50027868-5BDA8F14-EE77-4FD3-8927-E3486E8F4B96Q50042476-3430E339-DF33-4F61-AD1C-7870664D3E91Q50193302-72211A5A-0EF5-46B8-972B-28260AF2C771Q52661895-D64768F3-4C07-451D-B242-E3BF7EE9317AQ56956663-FAEBD445-A210-4B68-B1C0-4B472CA95FE8
P2860
Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Heart failure outcomes in clin ...... nts in patients with diabetes.
@en
type
label
Heart failure outcomes in clin ...... nts in patients with diabetes.
@en
prefLabel
Heart failure outcomes in clin ...... nts in patients with diabetes.
@en
P2860
P356
P1476
Heart failure outcomes in clin ...... nts in patients with diabetes.
@en
P2093
David H Fitchett
Silvio E Inzucchi
P2860
P356
10.1002/EJHF.633
P577
2016-09-21T00:00:00Z